Can Mounjaro Cause Liver Damage?

Step 1: What the trial data actually recorded

Across the SURMOUNT programme, involving thousands of adults taking tirzepatide over up to 72 weeks, there was no signal of drug-induced liver injury. Liver enzyme levels (the standard markers clinicians watch for hepatotoxicity) were not meaningfully elevated compared with placebo. The NHS medicines information for tirzepatide does not list liver damage among the known side effects, and the Summary of Product Characteristics for Mounjaro is consistent with that.

What did emerge in some analyses was something rather different: improvements in liver fat and liver inflammation markers among participants who had fatty liver disease at baseline. This matters because NAFLD and its more severe form MASH are closely linked with obesity and metabolic syndrome, the same conditions tirzepatide is licensed to treat. Researchers are now running dedicated trials on this basis. Semaglutide (Wegovy) has already received UK approval for MASH, and tirzepatide is following a similar research path.

So the short answer to whether Mounjaro causes liver damage is: no, based on current evidence. The longer answer begins below.

Step 2: Where genuine uncertainty exists, severe liver impairment

The clinical trials that led to Mounjaro's UK licence mostly excluded people with significant pre-existing liver disease. That means we have less data on how tirzepatide behaves in people with severe hepatic impairment (classified as Child-Pugh C). The prescribing guidance notes this gap and advises caution; in practice, a prescriber reviewing your consultation will ask about any liver conditions before deciding whether treatment is appropriate.

Mild to moderate liver impairment does not automatically rule Mounjaro out, and the pharmacokinetics of tirzepatide are not primarily liver-dependent (it is not metabolised through the same hepatic pathways as many other medicines). But this is precisely the kind of question that belongs with a clinician rather than a website. If you have a known liver condition, telling your prescriber in your consultation is essential.

Our clinical team (you can read more about how we work on our prescribers' page) reviews every submission individually. No algorithm clears a consultation; a named GPhC-registered Independent Prescriber reads your answers before any prescription is issued.

Step 3: The condition that is sometimes confused with liver problems

One reason people search whether tirzepatide damages the liver is because of abdominal discomfort during treatment, particularly in the first weeks after a dose increase. Most of this is gastrointestinal (nausea, bloating, a slowed digestive system) and settles with time. It is not liver pain.

What does require immediate attention is acute pancreatitis: severe, persistent stomach pain that may travel to the back, sometimes with vomiting. In January 2026 the MHRA issued a Drug Safety Update reminding prescribers and patients that pancreatitis is an infrequent but serious known risk with GLP-1 medicines. It can be confused with other upper-abdominal problems, including gallbladder issues (another known side effect listed for Mounjaro). If you develop sudden, severe pain in your upper abdomen that does not pass, go to A&E or call 999. You can report suspected side effects through the MHRA Yellow Card scheme.

For a broader look at how tirzepatide interacts with kidney function, our page on Mounjaro and kidney damage covers the evidence in the same detail.

Step 4: What to do before and during treatment if you have a liver condition

Tell your prescriber. That sounds obvious, but the consultation form is the place to record any liver diagnosis, any abnormal liver enzyme results, any history of alcohol-related liver disease, or any current medication your liver processes. There is no benefit to leaving something out; the clinical review exists precisely so that a prescriber can weigh those factors properly.

Once on treatment, a few practical steps reduce any theoretical strain. Alcohol, for example, places its own burden on the liver, and on Mounjaro's tolerability more broadly. Our page on drinking alcohol while on Mounjaro sets out what the evidence says there. Staying well hydrated matters too, because the nausea and vomiting that some people experience early in treatment can lead to dehydration if left unchecked.

If you're considering treatment and want to understand the full safety picture, the Mounjaro overview page covers mechanism, eligibility and the evidence base in full. Prescription costs and what's included in a private consultation are on the pricing page. And if you'd like to speak to our prescribers directly about your specific circumstances, starting a free consultation is the right first step, they can address liver health, medications, and anything else relevant to your situation.